Research progress of Ustekinumab in the treatment of inflammatory bowel disease

Front Immunol. 2024 Feb 22:15:1322054. doi: 10.3389/fimmu.2024.1322054. eCollection 2024.

Abstract

Inflammatory bowel disease (IBD) is a chronic, recurrent gastrointestinal disorder with elusive etiology. Interleukin-12 (IL-12) and IL-23 have emerged as key proinflammatory mediators/cytokines in IBD pathogenesis. Ustekinumab (UST), targeting IL-12 and IL-23, has demonstrated promising efficacy and safety in the treatment of IBD. Recently, UST has become increasingly favored as a potential first-line treatment option. This review delineates UST's mechanism of action, its clinical applications in IBD, including the response rates, strategies for dose optimization for case of partial or lost response, and potential adverse events. This review aims to offer a comprehensive understanding of UST's role as a therapeutic option in IBD management.

Keywords: Crohn’s disease; IL12/23; Ustekinumab; inflammatory bowel disease; ulcerative colitis.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cytokines / therapeutic use
  • Humans
  • Inflammatory Bowel Diseases* / drug therapy
  • Interleukin-12
  • Interleukin-23
  • Ustekinumab* / therapeutic use

Substances

  • Ustekinumab
  • Interleukin-12
  • Cytokines
  • Interleukin-23

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the National Natural Science Foundation of China (81870389, 82070565) (ML), (82200572) (XR), and by Science and Technology Projects in Guangzhou (202201020142).